Prove what agentic AI does for HCP engagement, before you buy a platform or go live.
We build the agent, run it on your data and your approved content, and prove it three ways before a single physician is involved. You leave with a business case built on your own numbers, no platform bought and nothing sent.
The problem
The only sanctioned way to learn is usually to go live. That makes learning expensive and late.
Every platform vendor is selling you agents. None will tell you what they are worth for your portfolio, or what clears Medical, before you have spent the money to find out. In pharma, learning usually means going live in front of a physician. That is promotional communication under MLR, and it triggers the Article 50 duty for an agent to identify itself. So the first real read on value and compliance arrives after the spend, not before. We break that.
How the pilot works
One agent, built on your data. Proven three ways before anyone goes live.
We build the agent and run it on anonymised segments and your own approved content. Then we prove it on three fronts, with no physician involved and nothing sent.
01
Medical sign-off read
Your own Medical reviews what the agent writes and tells you whether they would sign it, at scale. You see the approval bar before you build toward it.
02
Resonance read, directional
Simulated physician profiles show where the messaging lands and where it needs work. This is directional insight into message quality, not a predicted real-world response rate.
03
Reach and economics
We size the reachable tail against cost per contact and the price of a rep visit, so the value shows up in your own numbers.
Compliance, drawn early
The line the live step will have to hold, mapped from day one.
We start and document the Medical approval path, so the live step inherits it instead of starting cold. Promotion law, Medical review, adverse-event handling, and the EU AI Act Article 50 identification duty are on the table from the first session, not discovered after launch.
What you get
- →A working agent, shown on your data, writing from your approved content
- →A Medical sign-off read, would your own reviewers sign what it wrote, at scale
- →A resonance read from simulated physician profiles, directional, showing where messaging lands and where it needs work
- →The reachable tail sized against cost per contact and the price of a rep visit
- →A started, documented Medical approval path the live step inherits
- →A fundable business case, plus a clear go or no-go
Why us
We sell no platform, so the recommendation is yours.
Veeva, Salesforce, and the orchestration vendors all want the same deal. We do not. We build the agent, prove it, and hand you the evidence to choose what to buy and in what order. David Schärf has led market access, reimbursement, and product across DiGA, DTx, and pharma for over a decade, and has sat across the table from Medical, commercial, and payers. You get a senior operator, not a sales deck.
Start
Bring one brand. We will show you what the agent does with it.
The pilot runs on your data and your approved content and ends in a fundable business case with a clear go or no-go. Tell us the brand and the segment, and we will scope it.
See how your outreach lands, and improve it, before you send. No platform pitch.